Neural network analysis of clinicopathological and molecular markers in bladder cancer

Journal of Urology

Volumn 163, Issue 2, 2000, Pages 630-633

  Qureshi, Khaver N ^b   Naguib, Raouf N G ^b   Hamdy, Freddie C ^b   Neal, David E ^b   Mellon, J Kilian ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

Artificial neural network; Bladder neoplasms; c erbB 2; EGFR; p53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ARTICLE; ARTIFICIAL NEURAL NETWORK; BLADDER CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTO ONCOGENE; RETROSPECTIVE STUDY;

EID: 0033983145     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67948-7     Document Type: Article

References (29)

1. Walker, L.: The challenge we face, fighting cancer on all fronts. Cancer Research Campaign Scientific Yearbook. Park Communication Ltd.: London, p. 2, 1997-98
2. Pagano, F., Bassi, P., Galetti, T. P., Meneghini, A., Milani, C., Artibani, W. and Garbeglio, A.: Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumour, nodes and metastasis classification. J Urol, 145: 45, 1991
3. Anderstøm, C., Johansson, S. and Nilsson, S.: The significance of lamina propria invasion on the prognosis of patients with bladder tumours. J Urol, 124: 23, 1980
4. Cummings, K. B.: Carcinoma of the bladder: predictors. Cancer, 45: 1849, 1980
5. Liebert, M. and Seigne, J.: Characteristics of invasive bladder cancers: Histological and molecular markers. Semin Urol Oncol, 14: 62, 1996
6. Heney, N. M., Ahmed, S., Flanagan, M. J., Frable, W., Corder, M. P., Hafermann, M. D. and Hawkins, I. R.: Superficial bladder cancer: progression and recurrence. J Urol, 130: 1083, 1983
7. Parmar, M. K. B., Freedman, L. S., Hargreave, T. B. and Tolley, D. A.: Prognostic factors for recurrence and follow-up policies in the treatment of Ta/T1 bladder cancer: report from the British Medical Research Council Subgroup on Ta/T1 Bladder Cancer (Urological Cancer Working Party). J Urol, 142: 284, 1989
8. Smith, G., Elton, R. A., Beynon, L. L., Newsam, J. E., Chisholm, G. D. and Hargreave, T. B.: Prognostic significance of biopsy results of normal-looking mucosa in cases of Ta/T1 bladder cancer. Brit J Urol, 55: 665, 1983
9. Kiemeney, L. A. L. M., Witjes, J. A., Heijbroek, R. P., Koper, N. P., Verbeek, A. L. M., Debruyne, F. M. J. and the Members of the Dutch South-East Co-operative Urological Group: Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Br J Urol, 73: 164, 1994
10. Althausen, A. F., Prout, G. R. and Daly, J. J.: Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol, 116: 575, 1976
11. Kondo, I. and Schimizu, N.: Mapping of the human gene for epidermal growth factor receptor (EGFR) on the p13 leads to q22 region of chromosome 7. Cytogenet Cell Genet, 35: 9, 1983
12. Neal, D. E., Sharples, L., Smith, K., Fennelly, J., Hall, R. R. and Harris, A. L.: The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer, 65: 1619, 1990
13. Mellon, J. K., Wright, C., Kelly, P., Horne, C. H. W. and Neal, D. E.: Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol, 153: 919, 1995
14. Mellon, J. K., Lunec, J., Wright, C., Horne, C. H. W., Kelly, P. and Neal, D. E.: c-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol, 155: 321, 1996
15. Underwood, M., Bartlett, J., Reeves, J., Gardiner, D. S., Scott, R. and Cooke, T.: c-erbB-2 gene amplification: a novel marker in recurrent bladder tumors? Cancer Res, 55: 2422, 1995
16. Sato, K., Moriyama, M., Mori, S., Saito, M., Watanuki, T., Terada, K., Okuhara, E., Akiyama, T., Toyoshima, K., Yamamoto, T. and Kato, T.: An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer, 70: 2493, 1992
17. Hollstein, T., Sidransky, D,. Vogelstein, B. and Harris, C. C.: p53 mutations in human cancers. Science, 253: 49, 1991
18. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S. C., Nichols, P. W., Skinner, D. G., Jones, P. A. and Cote, R. J.: Accumulation of nuclear p53 and tumour progression in bladder cancer. N Engl J Med, 331: 1259, 1994
19. Naguib, R. N. G. and Sherbet, G. V.: Artificial neural networks in cancer research. Pathobiology, 65: 129, 1997
20. http.: //www.uroweb.nl/posters/paris96/27/index.html
21. Babaian, R. J., Fritsche, H. A., Zhang, Z., Zhang, K. H., Madyastha, K. R. and Barnhill, S. D.: Evaluation of ProstA-sure index in the detection of prostate cancer: a preliminary report. Urology, 51: 132, 1998
22. Snow, P. B., Smith, D. S. and Catalona, W. J.: Artificial neural networks in the diagnosis of prostate cancer: a pilot study. J Urol, 152: 1923, 1994
23. Naguib, R. N. G., Robinson, M. C., Apakama, I., Neal, D. E. and Hamdy, F. C.: Neural network analysis of prognostic markers in prostate cancer. Br J Urol, 77: 50, 1996
24. Naguib, R. N. G., Robinson, M. C., Neal, D. E. and Hamdy, F. C.: Neural network analysis of combined conventional and experimental prognostic markers in prostate cancer: a pilot study. Br J Cancer, 78: 246, 1998
25. Niederberger, C. S., Lipshultz, L. I. and Lamb, D. J.: A neural network to analyse fertility data. Fertil Steril, 60: 324, 1993
26. Wright, C., Mellon, K., Johnston, P., Lane, D. P., Harris, A. L., Horne, C. H. W. and Neal, D. E.: Expression of mutant p53, c-erbB2 and the epidermal growth factor receptor in transitional cell carcinoma of the urinary bladder. Br J Cancer, 63: 967, 1991
27. Neuralworks Professional II/Plus Reference Guide. Neuralware Inc.: Pittsburgh, 1995
28. McNemar, Q.: Note on the sampling error of the difference between correlated proportions or percentages. Psychometrica, 12: 153, 1947
29. th ed. Hafner: New York.